Rebecca Payne

Rebecca Payne

Auto-generated profile, based on publicly available information

Rebecca Payne

Department of Paediatrics, University of Oxford, Oxford OX1 3SY, United Kingdom

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 December 2006 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
PKPhotini Kiepiela
Photini Kiepiela
KNKholiswa Ngumbela
Kholiswa Ngumbela
CTChristina Thobakgale
Christina Thobakgale
DRDhanwanthie Ramduth
Dhanwanthie Ramduth
IHIsobella Honeyborne
Isobella Honeyborne
PGPhilip Goulder
Philip Goulder

20 April 2021 in Nature Medicine
Verified
Journal Article
Open access
PDF file
ESEmily Stephenson
Emily Stephenson
GRGary Reynolds
Gary Reynolds
RBRachel A. Botting
Rachel A. Botting
FCFernando J. Calero-Nieto
Fernando J. Calero-Nieto
MMMichael D. Morgan
Michael D. Morgan
MHMuzlifah Haniffa
Muzlifah Haniffa
Analysis of human blood immune cells provides insights into the coordinated response to viral infections such as severe acute respiratory syndrome coronavirus 2, which causes coronavirus disease 2019 (COVID-19). We performed single-cell transcriptome, surface proteome and T and B lymphocyte antigen receptor analyses of over 780,000 peripheral blood mononuclear cells from a cross-sectional cohort of 130 patients with varying severities of COVID-19. We identified expansion of nonclassical monocytes expressing complement transcripts (CD16+C1QA/B/C+) that sequester platelets and were predicted to replenish the alveolar macrophage pool in COVID-19. Early, uncommitted CD34+hematopoietic stem/progenitor cells were primed toward megakaryopoiesis, accompanied by expanded megakaryocyte-committed progenitors and increased platelet activation. Clonally expanded CD8+T cells and an increased ratio of CD8+effector T cells to effector memory T cells characterized severe disease, while circulating follicular helper T cells accompanied mild disease. We observed a relative loss of IgA2 in symptomatic disease despite an overall expansion of plasmablasts and plasma cells. Our study highlights the coordinated immune response that contributes to COVID-19 pathogenesis and reveals discrete cellular components that can be targeted for therapy.

25 February 2009 in Nature
Verified
Journal Article
Closed access
PDF file
YKYuka Kawashima
Yuka Kawashima
KPKatja Pfafferott
Katja Pfafferott
JFJohn Frater
John Frater
PMPhilippa Matthews
Philippa Matthews
RPRebecca Payne
Rebecca Payne
PGPhilip Goulder
Philip Goulder

1 November 2021 in Cell
Verified
Journal Article
Open access
RPRebecca P. Payne
Rebecca P. Payne
SLStephanie Longet
Stephanie Longet
JAJames A. Austin
James A. Austin
DSDonal Skelly
Donal Skelly
WDWanwisa Dejnirattisai
Wanwisa Dejnirattisai
AZAmira A.T. Zawia
Amira A.T. Zawia
Extension of the interval between vaccine doses for the BNT162b2 mRNA vaccine was introduced in the United Kingdom to accelerate population coverage with a single dose. At this time, trial data were lacking, and we addressed this in a study of United Kingdom healthcare workers. The first vaccine dose induced protection from infection from the circulating alpha (B.1.1.7) variant over several weeks. In a substudy of 589 individuals, we show that this single dose induces severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) neutralizing antibody (NAb) responses and a sustained B and T cell response to the spike protein. NAb levels were higher after the extended dosing interval (6–14 weeks) compared with the conventional 3- to 4-week regimen, accompanied by enrichment of CD4+ T cells expressing interleukin-2 (IL-2). Prior SARS-CoV-2 infection amplified and accelerated the response. These data on dynamic cellular and humoral responses indicate that extension of the dosing interval is an effective immunogenic protocol.

1 September 2008 in Journal of Virology
Verified
Journal Article
Open access
PDF file
PMPhilippa C. Matthews
Philippa C. Matthews
APAndrew Prendergast
Andrew Prendergast
ALAlasdair Leslie
Alasdair Leslie
HCHayley Crawford
Hayley Crawford
RPRebecca Payne
Rebecca Payne
PGPhilip J. R. Goulder
Philip J. R. Goulder
Much uncertainty still exists over what T-cell responses need to be induced by an effective human immunodeficiency virus (HIV) vaccine. Previous studies have hypothesized that the effective CD8 + T-cell responses are those driving the selection of escape mutations that reduce viral fitness and therefore revert posttransmission. In this study, we adopted a novel approach to define better the role of reverting escape mutations in immune control of HIV infection. This analysis of sequences from 710 study subjects with chronic C-clade HIV type 1 infection demonstrates the importance of mutations that impose a fitness cost in the control of viremia. Consistent with previous studies, the viral set points associated with each HLA-B allele are strongly correlated with the number of Gag-specific polymorphisms associated with the relevant HLA-B allele ( r = −0.56, P = 0.0034). The viral set points associated with each HLA-C allele were also strongly correlated with the number of Pol-specific polymorphisms associated with the relevant HLA-C allele ( r = −0.67, P = 0.0047). However, critically, both these correlations were dependent solely on the polymorphisms identified as reverting. Therefore, despite the inevitable evolution of viral escape, viremia can be controlled through the selection of mutations that are detrimental to viral fitness. The significance of these results is in highlighting the rationale for an HIV vaccine that can induce these broad responses.

1 April 2007 in Journal of Virology
Verified
Journal Article
Open access
PDF file
IHIsobella Honeyborne
Isobella Honeyborne
APAndrew Prendergast
Andrew Prendergast
FPFlorencia Pereyra
Florencia Pereyra
ALAlasdair Leslie
Alasdair Leslie
HCHayley Crawford
Hayley Crawford
PGPhilip J. R. Goulder
Philip J. R. Goulder
To better understand relationships between CD8+T-cell specificity and the immune control of human immunodeficiency virus type 1 (HIV-1), we analyzed the role of HLA-B*13, an allele associated with low viremia, in a cohort of 578 C clade-infected individuals in Durban, South Africa. Six novel B*13-restricted cytotoxic T lymphocyte epitopes were defined from analyses of 37 B*13-positive subjects, including three Gag epitopes. These B*13-restricted epitopes contribute to a broad Gag-specific CD8+response that is associated with the control of viremia. These data are consistent with data from studies of other HLA-class I alleles associated with HIV control that have shown that the targeting of multiple Gag epitopes is associated with relative suppression of viremia.